"When there's a big
proposal that would have a big impact like this, there's usually some kind of
analysis that's included in the rulemaking. It usually includes projections —
here there's nothing."
— Lindsay Bealor Greenleaf, vice president for policy at ADVI
Health LLC, spoke with AIS’s RADAR
on Drug Benefits about the confounding lack of details available on
CMS’s latest proposed rule to encourage value-based purchasing for expensive
drugs.
No comments:
Post a Comment